Full Product Name
DAG1 siRNA (Mouse)
Product Synonym Names
DAG-1; Dystroglycan; Dystrophin-associated glycoprotein 1
Product Gene Name
DAG1 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q62165
Specificity
DAG1 siRNA (Mouse) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of mouse DAG1 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of DAG1 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
DAG1 sirna
siRNA to inhibit DAG1 expression using RNA interference
Applications Tested/Suitable for DAG1 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for DAG1. It may not necessarily be applicable to this product.
NCBI Accession #
NP_001263410.1
[Other Products]
NCBI GenBank Nucleotide #
NM_001276481.1
[Other Products]
UniProt Primary Accession #
Q62165
[Other Products]
UniProt Secondary Accession #
Q61094; Q61141; Q61497[Other Products]
UniProt Related Accession #
Q62165[Other Products]
Molecular Weight
96,905 Da
NCBI Official Full Name
dystroglycan
NCBI Official Synonym Full Names
dystroglycan 1
NCBI Official Symbol
Dag1??[Similar Products]
NCBI Official Synonym Symbols
DG; Dp71; Dp427; D9Wsu13e
??[Similar Products]
NCBI Protein Information
dystroglycan
UniProt Protein Name
Dystroglycan
UniProt Synonym Protein Names
Dystrophin-associated glycoprotein 1
Protein Family
Dystroglycan
UniProt Gene Name
Dag1??[Similar Products]
UniProt Synonym Gene Names
Dag-1; Alpha-DG; Beta-DG??[Similar Products]
UniProt Entry Name
DAG1_MOUSE
UniProt Comments for DAG1
DAG1: a cytoskeletal protein that functions as a laminin receptor. Provides a linkage between the subsarcolemmal cytoskeleton and the extracellular matrix. May be involved in autosomal recessive muscular dystrophies. Its dramatic reduction in Duchenne muscular dystrophy leads to a loss of linkage between the sarcolemma and extracellular matrix, rendering muscle fibers more susceptible to necrosis. Dystroglycan also functions as dual receptor for agrin and laminin-2 in the Schwann cell membrane. Binds to several types of arenaviruses. Is a target for the entry of Mycobacterium leprae into peripheral nerve Schwann cells. The muscle and nonmuscle isoforms of dystroglycan differ by carbohydrate moieties but not protein sequence.
Protein type: Motility/polarity/chemotaxis; Cytoskeletal; Membrane protein, integral
Cellular Component: dystroglycan complex; extracellular space; focal adhesion; costamere; basolateral plasma membrane; extracellular region; integral to membrane; intercellular junction; lipid raft; nucleoplasm; dystrophin-associated glycoprotein complex; postsynaptic membrane; cell-cell adherens junction; cytoskeleton; membrane; lamellipodium; cytoplasm; plasma membrane; basement membrane; synapse; nucleus; cell junction; sarcolemma; filopodium
Molecular Function: tubulin binding; protein binding; structural constituent of muscle; protein complex binding; SH2 domain binding; calcium ion binding; alpha-actinin binding; actin binding; vinculin binding
Biological Process: nerve maturation; Schwann cell development; negative regulation of protein kinase B signaling cascade; viral reproduction; cytoskeletal anchoring; negative regulation of MAPKKK cascade; virus-host interaction; membrane protein ectodomain proteolysis; morphogenesis of an epithelial sheet; calcium-dependent cell-matrix adhesion; NLS-bearing substrate import into nucleus; negative regulation of cell migration; myelination in the peripheral nervous system
Research Articles on DAG1
1. Phosphorylation within the cysteine-rich region of dystrophin enhances its association with beta-dystroglycan and identifies a potential novel therapeutic target for skeletal muscle wasting.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
